Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Universite Paris-Est Creteil Val De Marne currently manages a portfolio focused on the Medical Devices & Mechanical Engineering technology area. The data shows 1 pending office action across the entire portfolio, indicating a specific window of active prosecution. This 1 pending action is being reviewed within 1 distinct art unit, suggesting a specialized technical focus for the current filings. The limited scope of active matters suggests that the applicant is pursuing a targeted patent strategy.
The prosecution is handled by 1 distinct examiner, ensuring a consistent point of contact for the applicant. SARAH B LEDERER serves as the busiest examiner for this entity, with 1 pending office action currently assigned. Because the total number of pending actions matches the count for the busiest examiner, the portfolio's immediate administrative requirements are concentrated under this 1 individual. This structure simplifies the tracking of deadlines and examiner interactions for the legal team involved, as there are no other pending actions across different art units to manage at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEKHLIN, ELI S | 1 | 60.4% | +48.1% |
| DEVI, SARVAMANGALA | 1 | 65.5% | +55.5% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721890 | METHOD FOR DELITHIATING AT LEAST ONE LITHIUM AND TRANSITION-METAL NITRIDE | MEKHLIN, ELI S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721890 | METHOD FOR DELITHIATING AT LEAST ONE LITHIUM AND TRANSITION-METAL NITRIDE | MEKHLIN, ELI S | — |
| 18269113 | CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS | DEVI, SARVAMANGALA | — |
| 18036237 | ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1725 | 1 |
| 1645 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18721890 | METHOD FOR DELITHIATING AT LEAST ONE LITHIUM AND TRANSITION-METAL NITRIDE | MEKHLIN, ELI S | 1725 | §102§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18269113 | CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS | DEVI, SARVAMANGALA | 1645 | §112 | Final Rejection | — | Pending | Jun 22, 2023 |
| 18036237 | ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | — | Pending | May 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE PARIS EST CRETEIL VAL DE MARNE has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Eli S Mekhlin has the most, with 1 of UNIVERSITE PARIS EST CRETEIL VAL DE MARNE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
